•Combination therapy with an anti-PD-L1 backbone and either an anti-CTLA-4 immune checkpoint inhibitor (ICI) or anti-VEGF therapy remains standard of care in the first-line setting for advanced HCC. This evidence concerns the gene VEGFA and hepatocellular carcinoma.